Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).
Abraham J, Coleman R, Elias A, Holmes FA, Kalinsky K, Kittaneh M, Lower E, Mahtani R, Terry Mamounas E, Pegram M, Vogel C; Breast Cancer Therapy Expert Group (BCTEG). Abraham J, et al. Among authors: kittaneh m. Breast Cancer Res Treat. 2018 Aug;171(1):11-20. doi: 10.1007/s10549-018-4783-1. Epub 2018 May 4. Breast Cancer Res Treat. 2018. PMID: 29725889 Review.
A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer.
Mahtani R, Holmes FA, Badve S, Caldera H, Coleman R, Mamounas E, Kalinsky K, Kittaneh M, Lower E, Pegram M, Press MF, Rugo HS, Schwartzberg L, Vogel C; Breast Cancer Therapy Expert Group (BCTEG). Mahtani R, et al. Among authors: kittaneh m. Clin Breast Cancer. 2020 Jun;20(3):e251-e260. doi: 10.1016/j.clbc.2019.08.001. Epub 2019 Aug 21. Clin Breast Cancer. 2020. PMID: 32139271 Review.
Advances in Therapeutic Approaches for Triple-Negative Breast Cancer.
Mahtani R, Kittaneh M, Kalinsky K, Mamounas E, Badve S, Vogel C, Lower E, Schwartzberg L, Pegram M; Breast Cancer Therapy Expert Group (BCTEG). Mahtani R, et al. Among authors: kittaneh m. Clin Breast Cancer. 2021 Oct;21(5):383-390. doi: 10.1016/j.clbc.2020.12.011. Epub 2020 Dec 29. Clin Breast Cancer. 2021. PMID: 33781662 Review.
Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG).
Abraham J, Caldera H, Coleman R, Elias A, Goetz MP, Kittaneh M, Lower E, Mahtani R, Terry Mamounas E, Pegram M, Rugo H, Schwartzberg L, Traina T, Vogel C. Abraham J, et al. Among authors: kittaneh m. Breast Cancer Res Treat. 2018 May;169(1):1-7. doi: 10.1007/s10549-018-4662-9. Epub 2018 Jan 19. Breast Cancer Res Treat. 2018. PMID: 29352368 Free PMC article. Review.
Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG).
Kittaneh M, Badve S, Caldera H, Coleman R, Goetz MP, Mahtani R, Mamounas E, Kalinsky K, Lower E, Pegram M, Press MF, Rugo HS, Schwartzberg L, Traina T, Vogel C. Kittaneh M, et al. Clin Breast Cancer. 2020 Jun;20(3):183-193. doi: 10.1016/j.clbc.2020.01.001. Epub 2020 Jan 8. Clin Breast Cancer. 2020. PMID: 32014370 Free article. Review.
26 results